Abstract: Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a poly ether moiety at the 4?-position of the phenyl ring of the compound.

Abstract: A system for extracting carbon source from sewage sludge in sewer pipes through online organic and inorganic component separation includes an outer system box, where the outer system box is provided therein with a system body; the system body includes a deodorization module, a pre-treatment module, and a cyclone separation module that are sequentially connected from top to bottom; an upper side wall of the cyclone separation module is provided with an oversize residue pressing module; and the pre-treatment module, the cyclone separation module, and the oversize residue pressing module are electrically connected to a control module. The present disclosure achieves online and on-site quick treatment of the sewage sludge in the sewer pipe, and solves common practical problems arising in the existing centralized treatment and disposal method of sewage sludge in the sewer pipe.

Abstract: Systems and methods for cleaning an edge ring pocket are described herein. One of the methods includes providing one or more process gases to a plasma chamber, supplying a low frequency (LF) radio frequency (RF) power to an edge ring that is located adjacent to a chuck of the plasma chamber. The LF RF power is supplied while the one or more process gases are supplied to the plasma chamber to maintain plasma within the plasma chamber. The supply of the LF RF power increases energy of plasma ions near the edge ring pocket to remove residue in the edge ring pocket. The LF RF power is supplied during the time period in which a substrate is not being processed within the plasma chamber.

Abstract: A recycle apparatus includes a conveyor, a flattening device, and a cutting tool. The conveyor includes a first roller and a second roller opposite to each other. The flattening device is located aside the first roller and the second roller. The cutting tool is located aside the flattening device. The flattening device is located between the first roller and the second roller of the conveyor and the cutting tool. The first roller and the second roller is configured to press and feed the photovoltaic module to the flattening device for allowing the photovoltaic module to be flattened by the flattening device, and then the flattened photovoltaic module is fed to the cutting tool by the first roller and the second roller for allowing the back sheet to be separated from the glass sheet assembly by the cutting tool.

Abstract: Intravascular imaging catheters are provided that include a distal sheath portion having a lumen that is configured to optionally receive a guidewire or an imaging assembly. The distal sheath portion may be configured to have dimensions such that when a guidewire is inserted through the lumen and extends through a distal exit port, the distal sheath portion may be employed as a microcatheter. External tissue may be imaged at a location at or near the distal end of the catheter, enabling, for example, the controlled imaging of a total occlusion, and the positioning of the distal end (and guidewire) within a true lumen associated with a total occlusion. A structural stop may be provided at or near the distal end of the distal sheath portion to prohibit extension of the imaging assembly out of the distal exit port, while permitting the extension of the guidewire through the distal exit port.

Abstract: A condensed cyclic compound and an organic light-emitting device including the condensed cyclic compound are provided. The condensed cyclic compound is represented by Formula 1. The A3 ring of Formula 1 is a group represented by Formula 2A or a group represented by Formula 2B. The organic light-emitting device includes: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode and including an emission layer, the organic layer including at least one of the condensed cyclic compound represented by Formula 1.

Abstract: A large-area wrinkled graphene substrate capable of being manufactured in a large-area, and a method for manufacturing the same is provided. A method for manufacturing a wrinkled graphene substrate includes: i) providing a graphene unit; ii) inserting a carrier film and a graphene unit between a pair of rolls and rotating the pair of rolls in opposite directions to attach a carrier film on the graphene unit, iii) immersing the graphene unit in an etching solution to provide graphene, iv) between a pair of rolls, graphene and poly(4-styrene sulfonic acid)/polystyrene (PSS/PS) substrate attaching graphene onto the PSS/PS substrate, v) attaching an ethylene vinyl acetate/polyethylene terephthalate (EVA/PET) substrate to wrinkled graphene on PSS/PS substrate by inserting EVA/PET and WGr/PSS/PS stack between the rolls, viii) removing the PSS/PS substrate by immersing PET/EVA/WGr/PSS/PS stack in water, and ix) providing a wrinkled graphene substrate on the EVA/PET substrate.

Abstract: Aspects relate to method of zinc-comprising nanowire fabrication, the method comprising forming a starting material comprising zinc metal or zinc metal alloy and at least one reactive metal, and exposing the starting material to one or more alcohols to obtain a reaction product comprising zinc-comprising nanowires, wherein the at least one reactive metal is more reactive than zinc to the one or more alcohols.

Abstract: Provided are a method and apparatus for evaluating a degree of frequency regulation urgency of a generator set, a power system and a storage medium.

Abstract: The present invention relates to a new use of compounds that are angiotensin II (Ang II) agonists, more particularly agonists of the Ang II type 2 receptor (the AT2 receptor), and especially agonists that bind selectively to the AT2 receptor, for the prevention or treatment of muscular dystrophy or complications associated with muscular dystrophy.

Abstract: The present inventions relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.

Abstract: A human-robot system and method for performing an agricultural task, the system including: a robotic manipulator with an agricultural tool coupled to an end effector thereof; an imaging device adapted to capture imagery of a target, the imaging device mechanically coupled to the end effector; a laser distance sensor adapted to measure a distance between the manipulator and the target, the laser distance sensor mechanically coupled to the end effector and collocated with the imaging device; and a control unit including: a processing unit, a monitor and a human-machine interface (HMI), wherein the processing unit is configured to display the imagery on the monitor and to receive markings from the HMI and calculate a trajectory for the manipulator to perform the agricultural task with the tool.

Abstract: The present invention relates to an image encoding method and an image decoding method. The image decoding method includes partitioning a picture into a plurality of coding units, constructing a coding unit group including at least one coding unit of the plurality of coding units, obtaining coding information in units of one coding unit group, and decoding at least one coding unit of the plurality of coding units included in the coding unit group by using the obtained coding information.

Abstract: A method for search construct validation is described. The method includes determining a construct of a search query recognized on a search engine of a third party webpage and related constructs represented in a plurality of search results generated based on the search query. The method includes mapping the determined construct to the related constructs represented in the plurality of search results generated based on the search query. The method includes generating a knowledge graph illustrating the mapping between the determined construct and the related constructs and a hierarchy and a strength of a conceptual relationship between the determined construct and the related constructs. The method includes displaying, via an interactive user interface, an interactive graph illustrating the mapping between the determined construct and the plurality of related constructs and the hierarchy and the strength of the conceptual relationship between the determined construct and the plurality of related constructs.

Abstract: A method for electrostatically clamping an edge ring in a plasma processing chamber with an electrostatic ring clamp with at least one ring backside temperature channel for providing a flow of gas to the edge ring is provided. A vacuum is provided to the at least one ring backside temperature channel Pressure in the backside temperature channel is measured. An electrostatic ring clamping voltage is provided when the pressure in the backside temperature channel reaches a threshold maximum pressure. The vacuum to the backside temperature channel is discontinued. Pressure in the backside temperature channel is measured. If pressure in the backside temperature channel rises faster than a threshold rate, then sealing failure is indicated. If pressure in the backside temperature channel does not rise faster than the threshold rate, a plasma process is continued, using the backside temperature channel to regulate a temperature of the edge ring.

Abstract: Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175. Clinically, the albumin pharmaceutical composition can effectively reduce undesirable responses, such as rash, urticaria, anaphylaxis and possible immune responses in the human body caused by albumin polymers and dimers, thereby further ensuring the safety in clinical medication.

Abstract: A system and a method for increasing permeability of a brain barrier selected from a blood-brain barrier or a blood-cerebrospinal fluid barrier by controlled application of pulsed electric fields.

Abstract: This invention provides minimally invasive methods, reagents, diagnostic and prognostic markers useful for staging, prognosis and surveillance of colorectal cancers, and therapeutic intervention in individuals with colorectal cancers, or individuals who may be susceptible to developing colorectal cancers.

Abstract: The present disclosure relates to a connector assembly and a corresponding method to reverse polarity of the connector. The method enables polarity reversal without bending/twisting optical fibers within the connector assembly.

Abstract: In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid prodrug (e.g., galangin prodrug).